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Background: People with HIV are living longer with potent antiretroviral therapy (ART), and HIV is increasingly
complicated by other chronic medical comorbidities. The objective of this study was to explore HIV-positive
patients’ perspectives on living with HIV and diabetes mellitus (DM) or hypertension (HTN) and factors affecting
medication adherence.
Methods: We conducted six focus groups. Two investigators independently coded transcripts for thematic content
using editing style analysis. Codes were grouped into conceptual themes using consensus process.
Results: Thirty-five HIV-positive patients with diabetes or hypertension participated. Four major themes emerged: (1)
Comorbidities are a source of concern and frustration, sometimes eclipsing concern regarding HIV (2) Understanding of
health conditions and medications promotes adherence, (3) Simpler regimens with fewer side effects promote
adherence, and (4) Untreated substance abuse and mental health issues hinder adherence.
Conclusions: HIV-positive patients in this study voiced concern regarding medical comorbidities and highlighted
patient understanding, regimen factors, and substance abuse/mental health issues as barriers to adherence. Addressing
these issues may improve outcomes in the aging HIV-positive population. Adherence to medications among
HIV-positive patients with DM or HTN may be influenced by providing targeted disease-specific education, simplifying
regimens, and treatment of substance abuse/mental health issues.
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Since the widespread adoption of potent antiretroviral
therapy (ART) in the United States, AIDS deaths have
decreased and HIV has become a chronic illness [1]. As
a result, HIV-positive patients have increasing morbidity
and mortality from other chronic conditions including
diabetes mellitus (DM), hypertension (HTN), and car-
diovascular disease [1,2]. DM and HTN are common in
HIV-positive patients, with reported DM prevalence in
HIV ranging from 2-14% [3,4] and HTN prevalence re-
ported at 31.7% (56.4% in HIV-infected men older than
50) [5]. The prevalence of DM and HTN increases with
increasing age. As a result, these conditions will be in-
creasingly important in the management of HIV disease* Correspondence: amonroe4@jhmi.edu
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reproduction in any medium, provided the oras more people over age 50 are newly infected with HIV
and the current HIV-infected population ages [6].
Among HIV-positive patients, comorbidity is common
with an average of four to five comorbidities among people
older than 50 [7]. Increasing comorbidities are associated
with an increase in polypharmacy (taking more than five
medications) [7], which may worsen medication adherence
due to increased regimen complexity or “pill fatigue”. It is
unclear if and how patients take medications for their HIV
infection compared to their other comorbid conditions, al-
though early work has shown less adherence to medica-
tions for diabetes compared with antiretrovirals [8].
The majority of HIV-positive patients who are engaged
in care take ART and achieve an undetectable HIV RNA
level [9]. This requires adherence to both clinic visits and
medication therapy. Control of other comorbidities requires
additional lifestyle changes, such as healthy diet and regular
exercise, in addition to adherence to medication therapy.
However, little is known about patient perspectives onl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Overall sample characteristics (N = 35)
Characteristic N (%)
Male sex 19 (54)
Mean age (SD), years 50.8 (5.1)




Median duration of HIV (IQR), years 13 (5, 18)
Median duration of diabetes (IQR), years† 5 (2, 9)
Median duration of hypertension (IQR), years‡ 7 (2, 17)
Median duration of relationship with care
provider (IQR), years
5 (3, 9)
†Diabetics N = 12.
‡Hypertensives N = 32.
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DM and HTN. How HIV-positive patients approach the
management of their multiple medical conditions requires
further exploration to optimize care of these patients. The
objective of this study was to explore HIV-positive patients’
perspectives on living with DM or HTN and factors affect-
ing medication adherence among individuals with HIV and
other comorbidities. We hypothesized that among patients
with HIV and other comorbidities, adherence to HIV medi-
cations and avoiding complications of HIV disease would
be of higher priority.
Methods
Study design
We conducted six focus groups with a total of 35 partic-
ipants with HIV and DM or HTN recruited from an
HIV clinic in Maryland. All groups were conducted be-
tween February and March 2011. We chose focus groups
so that the group exchange would facilitate discussion
about barriers to and facilitators of treatment adherence
when living with multiple medical comorbidities. This
study received approval from the Johns Hopkins Medicine
Institutional Review Board and all participants provided
written informed consent. Participants were ensured of
the confidentiality of the group and instructed not to dis-
cuss the group proceedings with others.
Participants
We recruited participants from the clinic using self-referral
from flyers and through referral from medical providers.
We used this selection process to increase feasibility of re-
cruitment. Potential participants directly telephoned one of
the investigators (AM) for a final determination of eligibil-
ity for the study. Individuals were eligible to participate if
they received HIV care at a Baltimore-area HIV clinic, were
on medication therapy for both HIV infection and either
DM and/or HTN, were older than 18 and were English-
speaking. Medical chart review confirmed the presence of
HIV and DM or HTN and medication use. All participants
were compensated $50 and two bus tokens for participa-
tion in the study.
Data collection
One of the investigators (TR) led the groups using a dis-
cussion guide (Additional file 1) designed to collect data
on disease-specific knowledge and attitudes, management
of the patients’ various conditions, and barriers to and fa-
cilitators of adherence. Groups lasted about one hour.
Each group was facilitated by the same investigator (TR),
and another investigator (AM) audio-recorded, observed,
and took handwritten notes during each group. One in-
vestigator (AM) practiced in the clinic from which the
participants were recruited, but did not directly care for
any of the study participants.Prior to the group, participants completed a brief
questionnaire that included demographic data and data
regarding duration of HIV infection and of duration of
relationship with care provider. Data collection ceased
when thematic saturation occurred.Data analysis
Digital recordings of the focus group sessions were tran-
scribed verbatim. Participant identifiers were not tran-
scribed. Two investigators (AM and TR) coded all passages
using an editing style analysis, segmenting the data by
identifying information pertinent to the research question
then categorizing and giving identifying names (codes) to
the patterns that emerged [10]. We generated code lists
and conceptual themes through an iterative process of dis-
cussion and review. This process began with the two inves-
tigators separately coding several initial transcripts and
then meeting to discuss common findings and key themes.
From there, we developed a code book to guide the ana-
lysis of the remaining transcripts. Throughout the process,
investigators continually met and reviewed findings. Any
discrepancies were discussed and resolved by consensus.
ATLAS.ti 6.0 (Scientific Software Development GmbH,
Berlin) was used for data management and to facilitate
analysis. Questionnaire data was analyzed using Stata ver-
sion 11.0 (College Station, TX).Results
Participant characteristics
The characteristics of study participants (N = 35) are shown
in Table 1. The mean age of the overall sample was 51 years
(range 43–63), 54% of participants were male, and 91.4%
were black. Median duration of relationship with HIV care
provider was five years. The median duration of HIV infec-
tion was longer than that of DM or HTN.
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with HIV and diabetes (DM) and/or hypertension (HTN)
We identified four themes related to medication adher-
ence among patients with HIV and DM or HTN. We
present patients’ reflections by theme. Table 2 lists the
themes and subthemes, and the number of focus groups
in which each theme and subtheme was discussed.
Theme 1: Comorbidities are a source of concern and
frustration, sometimes eclipsing concern regarding HIV
Participants expressed concern about their comorbidities.
Achieving control of DM or HTN was perceived as neces-
sary to avoid complications of comorbidities. Participants
described family members’ experiences with complications
of DM and HTN, including heart attack, dialysis, and limb
amputation. Concern about adverse consequences of un-
controlled HTN is illustrated by the following quotations:
“I got the HIV, I ain’t going to worry about that. I have to
worry about having a heart attack or a stroke,” and “Do I
want to live to see my four-year-old grandson, or do I not
want to take my high blood pressure medicine and watch
my diet and watch what I eat because, like [my doctor] said,
HIV is not going to kill me. It’s the high blood pressure.”
Many participants described that taking their HIV medi-
cations had led to suppression of HIV and improvements
in health. However, control of comorbidities seemed more
elusive, and non-control was a source of frustration, par-
ticularly when multiple medications did not control the
condition: “Cause they got me taking like three or four pills
for my pressure and it still is not controlling it. So if they
could give me like one pill that I could take and it con-
trolled my pressure I’d be better with that,” and “MyTable 2 Themes and subthemes
Theme Number of
groups
Theme 1: Comorbidities generate concern
and frustration
5
Theme 2: Understanding of health conditions
and medications promotes adherence
6
Subthemes:
● Understanding the effects of missed doses
of medication (6)
6
● Linking disease manifestations and/or
symptoms to not taking medication
6
Theme 3: Simpler regimens with fewer side
effects promote adherence
4
Theme 4: Untreated substance abuse and
mental health issues hinder adherence
6
Subthemes:
● Substance abuse leads to difficulty engaging
with and staying in care
5
● Depression contributes to non-adherence to
medications and lifestyle recommendations
5problem for me is my diabetes . . . they just uncontrollable
. . . I don’t care what I eat or what I do, they will do what
they want to do.”
In addition to concern about DM and HTN, participants
mentioned hepatitis C, asthma/COPD osteoporosis, and
sarcoidosis as other comorbid conditions of concern to
them. The patients who mentioned conditions with signifi-
cant physical manifestations (asthma manifested through
shortness of breath) reported taking medications for those
conditions regularly. This was similar to patients who had
physical manifestations of their HIV/AIDS reporting in-
creased adherence to ART (discussed in Theme 2).
Theme 2: Understanding of health condition
reinforces adherence
Patients described the effect of understanding their condi-
tion on medication adherence. One subtheme was under-
standing the consequences of missed doses of medication.
Regarding HIV, this was expressed by patients who knew
that missed antiretroviral doses lead to resistance, “And the
thing is with Atripla is you can’t miss . . . if you miss, your
[drug] levels will go back down. So they’d have to take you
off of them and put you on something else.” Other patients
gave less weight to missed doses, which may have reflected
less understanding of how the medications work. Alterna-
tively, those patients may not have experienced or may not
have been educated about the effects non-adherence. This
was expressed both with regards to antiretrovirals, “I mean,
you’ve got it in your system. It’s not like if you miss one day
all of those going to be completely gone out of you . . . If you
miss a day it ain’t gonna hurt nothing. You just jump back
on it tomorrow,” and blood pressure medications, “The
medicine is . . . cumulative, so you miss a day you shouldn’t
get a headache right away . . . because it accumulates in
your body.”
Another subtheme was linking disease manifestations
and/or symptoms to not taking medication. Some partici-
pants expressed that experiencing physical manifestations
of their illnesses motivated them to adhere to prescribed
treatments. For example, participants who had been ad-
mitted with complications of AIDS or told that they were
going to die if they did not take antiretroviral therapy
expressed that as a motivating factor for continuing their
HIV medications, as follows, “And she retested me and
found out that I was HIV positive . . . I was almost gone
when she got me, and she worked with me and said . . .
‘You’ve got to do this.’ . . . And it was a no-brainer to me. If
I don’t take these medications, I’m gonna die. . . I did
everything she told me to do and I’m undetectable.” Simi-
larly, participants who had experienced physical manifes-
tations of their elevated blood pressure expressed strong
motivation to continue with their antihypertensive medi-
cations, “In the morning I take my high blood pressure
medicine . . . I know to take it . . . because I don’t want
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take mine as prescribed.” When participants did not feel
symptoms of their comorbid illness, less regular adherence
was reported, “With the high blood pressure medicine . . .
some days I feel better I don’t take it. I don’t take it like I
should . . . it gives [other patients] migraines and things
like that. With something like that, if I was at that stage
then I would be more sensible of taking it. . . But since I’m
not at the stage . . . I take it when I feel . . . that I need it.”
Theme 3: Simpler regimens with fewer side effects
promote adherence
Participants frequently commented on the burden of
their medication regimens. As an extreme example, “It’s
difficult for me because I take 22 pills a day and I take
six shots of insulin. That’s just too much medication. . .
It’s too much and, you know, I cry every day because I
just don’t feel like taking all those pills.” Furthermore,
participants expressed concerns about the side effects of
all the different medications, particularly when combined,
“Have you ever watched the TV and they tell you about a
simple drug and they then say, okay, but it can cause heart
disease, stroke . . . all this just from one pill. So just im-
agine. You might have 50 side effects from one pill so just
imagine all of the side effects you have from the different
HIV medicines and your blood pressure medicines going
together, ” and “One time they put me on two or three dif-
ferent high blood pressure medicines, then I started feeling
sleepy and heavy, . . . and the numbers dropped . . . but I
was feeling like I was medicated. So then I–well and now I
just give up.”
Patients who did have simplified regimens expressed
their satisfaction with those regimens for HIV, “But this
last [regimen], I can thank God that I’m not detectable
and . . . this one is great-just one pill once a day,” and
for diabetes, “my insulin . . . I was taking like 4 shots . . .
Now I got the pen. The new pen that I stick myself twice,
one in the morning, one in the evening. And that’s
awesome.”
Theme 4: Untreated substance abuse and mental health
issues hinder adherence
Some participants described difficulty engaging in care
for HIV and their other conditions because of substance
abuse, “[When] I was getting high smoking crack and using
drugs, I really didn’t care whether I was HIV-positive and
high blood pressure or anything,” and, “Now when I was
out there using I wasn’t a responsible addict where I could
say well, I’m going to take my HIV medications and blood
pressure pills every day.” They recognized that drug ab-
stinence facilitates medication adherence, as expressed by
several participants: “A lot of people who think that when
they hear HIV they think it’s a death sentence . . . but if
you start applying to the medication then you’ll see thedifference in your life. If you stop getting high your lifestyle
will change and start praying or whatever you have to do,”
and, “[My husband] relapsed and I had to go. Because I
know if I relapse, that’s like killing myself. I relapse, I drink a
beer, I’m going to the next thing . . . I’m not going to take my
medicine. I’m not going to take my medicine or my viral
load everything is going, blood pressure, everything. My
psych medicine. I’m going to start acting crazy erratic . . .
And I have abused my medication before. Getting high. Tak-
ing Trazodone to bring me down. Taken Depakote to bring
me up. Along with street drugs. I’ve done this, you know.”
Participants discussed how mental health issues, par-
ticularly depression, contributed to non-adherence to
medications. “I got so much depressed where I have missed
like, I’d say like three months [of pills], and I had to go back
. . . in a psych ward ‘cause I was thinking about hurting my-
self . . . I stayed up there on a psych ward for like a whole
month- -‘cause I wasn’t ready to come back out on the
street.” Some patients discussed the negative effects of
depression on trying to maintain lifestyle modification rec-
ommendations for DM or HTN, “Sometimes my depres-
sion takes me to indulge in things that ain’t good for me . . .
I had to reflect on that and snap out of it. You know, be-
cause before I catch myself, I’m . . . at 280 [pounds].”
In addition to the themes described above, another
factor influencing adherence among some participants
was social support. Examples of social support that rein-
forced adherence were having someone who lived with a
participant reminding him or her to take medication and
networking with other HIV-positive individuals within and
outside of the clinic. A barrier to adherence reported by
some participants was navigating the complex systems of
insurance and medication coverage, although this was not
uniformly reported.
Discussion
Patients described a variety of factors influencing adher-
ence to their medications for HIV, HTN, and DM. Four
main themes emerged: (1) Comorbidities generate concern
and frustration, sometimes eclipsing concern regarding
HIV (2) Understanding of health conditions and medica-
tions promotes adherence, (3) Simpler regimens with fewer
side effects promote adherence, and (4) Untreated sub-
stance abuse and mental health issues hinder adherence.
It appears that patients’ experiences with HIV, DM,
and HTN shaped their perceptions of the importance of
the illnesses. They described concerns regarding the ad-
verse consequences of uncontrolled DM and HTN, in-
corporating information from their experiences with
family members and from advice given by their medical
providers. Now that it is possible to control HIV with
ART, most patients actively engaged in HIV care are able
to achieve and maintain an undetectable HIV RNA [9].
Current estimates are that 75 – 79% of individuals
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acteristics of the patient, regimen, clinical setting, and
patient/provider relationship potentially limiting adher-
ence [13]. However, when HIV suppression is achieved,
patients and providers are able to shift their focus to ad-
dressing other chronic conditions like DM and HTN.
However, unlike HIV, these other conditions may not be
controlled through medication therapy alone. They often
entail additional self-care activities (shopping for healthy
food, exercising, etc.) that require specific knowledge and
skills that can be very time-intensive [14]. In attempting
to balance multiple health-related and non-health-related
competing demands, patients may not be able to devote
the time and resources necessary to control their comor-
bid conditions. Many participants in our groups, particu-
larly those who had well-controlled HIV, expressed
frustration that their DM or HTN was difficult to control
despite trying to follow their provider’s recommendations.
Factors contributing to non-adherence include poor
understanding of both a medication regimen and of the
relationship between antiretroviral non-adherence and
antiretroviral resistance [15-17]. Most of our participants
described the importance of taking their medications as
prescribed. However, those who had experienced HIV-
related illness or physical manifestations of DM or HTN
mentioned those episodes as particularly strong motiva-
tors of adherence.
Better medication adherence has been seen among indi-
viduals previously diagnosed with an AIDS-defining oppor-
tunistic infection [18] or with more advanced HIV [19] in
earlier studies. However, more recent studies either did not
examine AIDS-defining diagnosis as an HIV medication
adherence predictor [20] or did not find an association [21].
Among hypertensive patients, the belief that variations in
blood pressure are symptomatic is related to both better
adherence with antihypertensive agents and blood pressure
control [22]. However, many chronic conditions are asymp-
tomatic, and treatment of these chronic conditions is pri-
marily to prevent long-term morbidity and mortality, not
for short-term quality of life improvement [23] or symptom
relief. For patients who have not had symptomatic AIDS or
experienced symptoms from their HTN or DM, providers
must emphasize the importance of treatment for long-term
risk reduction even in the absence of symptoms. Patients
act on their beliefs and adhere to medications that help
them meet their goals [24]. One potential approach [25] is
for providers to align the patient’s beliefs about the identity
(symptoms), causes, timeline, control, and consequences of
their illness with medical knowledge. In this way, patients
will develop an adaptive understanding of their illness,
allowing for more productive self-management.
Additional factors reported as affecting adherence were
regimen pill burden/regimen complexity and presence of
side effects. For some of our focus group participants,the burden of non-antiretroviral regimens was higher
than the burden of antiretroviral regimens. Krentz and
colleagues [26] attempted to quantify the burden of non-
antiretroviral therapy in people with HIV, examining pat-
terns of antiretroviral and non-antiretroviral use among
HIV clinic patients over time (1990–2010). They found
that after peaking in 1998 at a mean of 12.1 pills per day,
the mean number of pills per day in 2010 was 6.7, with
22% of all patients taking more than 10 pills per day, and
antiretrovirals accounting for 40-50% of total pill burden.
In that study, the highest pill burden was among older pa-
tients with longer duration of HIV. As patients with HIV
age and have additional comorbidities, the number of daily
medications they use will increase, which poses a chal-
lenge to continued adherence to all medications.
Finally, participants described how untreated mental
health and substance abuse issues affected their medication
adherence, both to antiretroviral and non-antiretroviral
medications. Depression has consistently been associated
with medication nonadherence, not following advice from
providers, and missing appointments [27,28]. Thus, identi-
fying and treating depression is a crucial first step in con-
trolling HIV, which is dependent on medication adherence,
and controlling other comorbidities, which depends not
only on medication adherence but also on developing a
therapeutic alliance and instituting lifestyle changes. Sub-
stance abuse has also been associated with antiretroviral
nonadherence in several large prospective studies in HIV-
positive patients [29,30]. Our findings suggest that patients
were not adherent to any of their medications when their
substance abuse was not controlled, emphasizing the need
for effective substance abuse treatment for improving over-
all health outcomes.
Our data adds to the limited data regarding treatment
adherence in patients with HIV and DM or HTN. In a
recent study by Batchelder and colleagues of patients
with both HIV and DM [8], patients reported better
adherence to their antiretroviral medications compared
with their DM medications, which was not reported by our
study participants. Another finding from the Batchelder
study was that DM symptom burden was associated with
non-adherence to DM medications. Similarly, our partici-
pants described increased HTN-related symptoms when
they did not adhere to their antihypertensive medications.
Additional findings from the Batchelder study, specifically
that concerns regarding antiretroviral side effects and pres-
ence of depression were negatively associated with anti-
retroviral medication adherence, were similar to our results.
The authors did not find an association between concerns
regarding DM medication side effects or presence of de-
pression with DM medication adherence. They did not col-
lect information regarding substance abuse.
The major limitation of our study is that there is lim-
ited generalizability. Qualitative research collects detailed
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may not be applicable on a larger scale. The sample was
drawn from a single clinic and the participants were ra-
cially homogenous (almost entirely African-American). Al-
though more input from members of other racial groups
may have provided different insights, the burden of HIV in
the United States is disproportionately borne by African-
Americans, who represent 14% of the U.S. population but
46% of people living with HIV [31]. African-Americans
also have higher rates of DM and HTN, and develop HTN
earlier in life [32,33]. Therefore, exploring the perspectives
of African-Americans facing HIV and other chronic co-
morbidities is particularly relevant to the design of future
interventions targeting these issues. The median duration
of the relationship with the care provider among study
participants was five years. Establishment of a strong long-
term relationship with a care provider fosters good ad-
herence [34], and our results may have been different if
the participants had a shorter relationship duration with
their providers.
The major strength of our study is that it is an exam-
ination of the intersection of HIV management and co-
morbidity management. As patients with HIV live longer
and experience chronic comorbidities in addition to HIV,
these other comorbidities may contribute more to mor-
bidity and mortality than HIV itself, but control is of other
comorbidities is often elusive. This research adds to the
literature by bringing patients’ voices to the table, which
will aid in future intervention design to optimize comor-
bidity management among individuals with HIV.
Conclusions
To optimize treatment outcomes among an aging HIV-
positive population, control of comorbid DM and HTN is
required. Our findings that patient understanding, regi-
men factors, and substance abuse/mental health issues in-
fluence medication adherence are consistent with prior
studies regarding treatment adherence in HIV-positive pa-
tients. Our results suggest that there multiple targets for
improving medication adherence in a population with a
high risk for adverse outcomes. Adherence to medications
among HIV-positive patients with DM or HTN may be
improved by providing targeted disease-specific education,
simplifying regimens, and addressing substance abuse/
mental health issues.
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